JW Pharmaceutical Q1 2026 Operating Profit Surges 332% YoY; Revenue Up 8.8%

Preliminary Q1 2026 results (K-IFRS, separate, unaudited)
Revenue: 21,382M KRW (+1.3% QoQ, +8.8% YoY)
Operating profit: 2,883M KRW (+102.5% QoQ, +332.1% YoY)
Net income: 2,670M KRW (+13.5% QoQ, -68.9% YoY)
Pre-tax profit: 2,854M KRW (+324.3% QoQ, -67.7% YoY)
YoY net income decline due to base effect (prior year: 8,576M); operating profit improvement is notable

ADVERTISEMENT (250px+)